PDS Biotechnology Co. (NASDAQ:PDSB) Receives $14.25 Average Price Target from Analysts

PDS Biotechnology Co. (NASDAQ:PDSB) has been assigned an average rating of “Buy” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $14.25.

A number of research firms recently commented on PDSB. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a report on Tuesday. B. Riley reduced their price objective on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, June 12th. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st.

PDS Biotechnology Stock Down 0.3 %

PDSB stock opened at $3.20 on Friday. The company has a 50 day moving average of $3.34 and a two-hundred day moving average of $3.47. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The company has a market cap of $117.37 million, a price-to-earnings ratio of -2.35 and a beta of 1.88.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same period last year, the firm posted ($0.37) EPS. On average, equities analysts anticipate that PDS Biotechnology will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Kathleen S. Wright Associates Inc. bought a new position in shares of PDS Biotechnology in the first quarter worth about $28,000. Tempus Wealth Planning LLC bought a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $55,000. Ground Swell Capital LLC bought a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology in the second quarter worth $115,000. Finally, Squarepoint Ops LLC bought a new position in PDS Biotechnology during the second quarter worth $120,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.